SEARCH

SEARCH BY CITATION

References

  • 1
    Iyer S.P., Yao X., Crona J.H., Hoos L.M., Tetzloff G., Davis H.R. Jr, Graziano M.P., Altmann S.W. (2005) Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim Biophys Acta;1722:282292.
  • 2
    Clader J.W. (2004) The discovery of ezetimibe: a view from outside the receptor. J Med Chem;47:19.
  • 3
    McMasters D.R., Garcia-Calvo M., Maiorov V., McCann M.E., Meurer R.D., Bull H.G., Lisnock J., Howell K.L., Devita R.J. (2009) Spiroimidazolidinone NPC1L1 inhibitors. 1: discovery by 3D-similarity-based virtual screening. Bioorg Med Chem Lett;19:29652968.
  • 4
    Burnett J.R., Huff M.W. (2006) Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs;15:13371351.
  • 5
    Burnett D.A. (2004) Beta-lactam cholesterol absorption inhibitors. Curr Med Chem;11:18731887.
  • 6
    Wang Y., Qian H., Huang W., Zhang H., Zhou J. (2011) Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors. Lett Drug Des Discov;8:500505.
  • 7
    Wang Y., Zhang H., Huang W., Kong J., Zhou J., Zhang B. (2009) 2-Azetidinone derivatives: design, synthesis and evaluation of cholesterol absorption inhibitors. Eur J Med Chem;44:16381643.
  • 8
    Sampalis J.S., Bissonnette S., Boukas S. (2011) Effectiveness of ezetimibe in reducing the estimated risk for fatal cardiovascular events in hypercholesterolaemic patients with inadequate lipid control while on statin monotherapy as measured by the SCORE model. Adv Prev Med;2011:17.
  • 9
    Kashani A., Sallam T., Bheemreddy S., Mann D.L., Wang Y., Foody J.M. (2008) Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol;101:16061613.
  • 10
    Pfefferkorn J.A., Larsen S.D., Van Huis C., Sorenson R., Barton T., Winters T., Auerbach B. et al. (2008) Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption. Bioorg Med Chem Lett;18:546553.
  • 11
    Ritter T., Kvaerno L., Werder M., Hauser H., Carreira E.M. (2005) Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors. Org Biomol Chem;3:35143523.
  • 12
    Zhu X., Huang D., Lan X., Tang C., Zhu Y., Han J., Huang W., Qian H. (2011) The first pharmacophore model for potent G protein-coupled receptor 119 agonist. Eur J Med Chem;46:29012907.
  • 13
    Salisbury B.G., Davis H.R., Burrier R.E., Burnett D.A., Bowkow G., Caplen M.A., Clemmons A.L. et al. (1995) Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis;115:4563.
  • 14
    Farmer J.A., Gotto A.M. Jr (1995) Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab;9:825847.